Pinc PeptideThe girly peptide research blog

Guide · updated 8 October 2026

Peptide blends, checked against the evidence

Online sellers combine several peptides in one vial and sell them under names such as KLOW, GLOW, the Wolverine stack and CJC & Ipa3456. We found no published human study of these mixtures, and FDA found no human data at all for two common ingredients, TB-500 and KPV789101112. Blends also blur the cause of side effects: in two adverse-event reports, FDA said it could not judge one peptide’s role because the product held two913.

64 sources · 14 min read · By the Pinc Peptide editors

What are peptide blends?

A peptide blend is one product that holds two or more peptides. FDA’s 2026 review of BPC-157 calls these “multiple-API” products, meaning they have more than one active ingredient, and it found injectables and nasal sprays that pair BPC-157 with TB-500 or with a fragment of thymosin beta-49.

Online sellers offer blends in vials labeled for research use only414. Clinics and compounders have offered them too. FDA found clinic pages marketing a “regenerative combo” of KPV, BPC-157, TB-500, AOD9604 and follistatin-34412. Its 2024 review of CJC-1295 found it blended with ipamorelin, GHRP-2, GHRP-6, hexarelin, “fragment 176-191” and tesamorelin, and one outsourcing facility, a large compounder registered with FDA, reported making CJC-1295 with ipamorelin in 2019 and 202015.

Blend names are climbing in search: “wolverine stack” and “klow peptide” were among the rising US Google searches related to “bpc 157” in the 12 months to 29 September 202616.

Which blends are sold, and has any been tested?

The contents below are quoted from a regulator’s seizure list or a seller’s page34.

  • KLOW: Health Canada’s list of products seized from a Vancouver gym, published on 24 December 2025, includes “Klow 80 MG (BPC 10mg/TB-500 10mg/GHK-Cu 50mg/KPV 10mg)”3. A US-facing seller lists KLOW with the same four peptides14. We found no human study of it8.
  • GLOW: the same list includes “Glow 70 MG (BPC 10mg/TB-500 10mg/GHK-Cu 50mg)”, which is KLOW without KPV3. We found no human study of it8. The BPC-157 and GHK-Cu comparison covers whether anyone has tested that pair, which both KLOW and GLOW contain.
  • Wolverine stack: a popular name for BPC-157 with TB-500, and one seller’s product page is titled “BPC-157 10mg + TB-500 10mg (Wolverine Stack 20mg)”45. FDA’s reviews found no human study of the pair910.
  • CJC & Ipa or FIT Stack: CJC-1295 with ipamorelin, listed under those names by two sellers on 30 September 2026614. We found no published human study of the pair1117.
  • Tesamorelin with ipamorelin: FDA’s warning letters of 24 August 2026 name a “Tesamorelin Ipamorelin Blend” and “BIMORELIN”, which one seller’s page described as “combining Tesamorelin (10mg) and Ipamorelin (3mg)”1819. On 7 October 2026, PubMed held only review articles naming both peptides, and ClinicalTrials.gov listed no study of the pair12.
  • Sermorelin blends: sermorelin with GHRP-2, GHRP-6 or ipamorelin, sold online and made by compounders2021. We found no controlled trial of these mixes, only a 2017 chart review, with no control group, of 14 men who took sermorelin with GHRP-2 and GHRP-622. The ipamorelin and sermorelin comparison covers sermorelin with ipamorelin.
  • CagriSema: Novo Nordisk’s once-weekly injection of cagrilintide with semaglutide, which is not yet approved2324. A 68-week trial in 3,417 adults tested it against each drug alone and against placebo25.

What is the human evidence for each ingredient?

Most peptides in the gray-market blends above have little or no human evidence even on their own7910111226.

  • BPC-157: the published studies FDA found gave it to fewer than 100 people, for 2 weeks or less, and the only placebo-controlled trial in patients among them, for a bowel disease, found no clear benefit9.
  • TB-500: FDA found no human data by any route and no animal toxicity studies10.
  • GHK-Cu: small skin trials had mixed results, and we found no published study that injected it on its own in people82728.
  • KPV: FDA found no clinical study and no human exposure data by any route12.
  • CJC-1295: published human studies used only its long-lasting “with DAC” form, and we found no published study of fat loss, muscle or healing in people11151729.
  • Ipamorelin: its only published patient trial, in 114 adults after bowel surgery, found no clear benefit, and we found no study testing it in people for fat loss, muscle or sleep132630.
  • Tesamorelin: approved, as Egrifta, only for excess belly fat in adults with HIV, and its labels say it is not for weight loss3132.

What do studies show about the combinations?

For BPC-157 with TB-500, the closest evidence is two small studies, and neither tested the pair in people93334. In a 2026 study of rats with repaired Achilles tendons, 8 per group, combining the two added no benefit over either peptide alone33. In a 2021 chart review with no control group, 3 of 4 knee-pain patients given BPC-157 with “thymosin-beta-4 (TB4)”, as the paper calls it, reported significant pain relief34. FDA’s review also calls that peptide thymosin beta-4, which FDA says is not the same substance as TB-500910. The BPC-157 and TB-500 comparison sets out both studies.

For CJC-1295 with ipamorelin, sellers claim the two boost growth hormone more together, and FDA’s 2024 review of ipamorelin quotes one website promising a “3-5 fold increase”1315. We found no published human study testing that claim, and a 2026 review describes the practice as “largely driven by anecdotal rationale”1117. There is a second gap: FDA found some of these blends sold with CJC-1295 without DAC, a form it found no study giving to people, and others that did not say which form they held, while every published human result for CJC-1295 comes from the DAC form1529. The CJC-1295 and ipamorelin comparison covers the hormone studies behind the claim and which CJC-1295 is in the blend.

What does a tested combination look like?

CagriSema, which pairs cagrilintide with semaglutide, shows what testing a combination involves. In Novo Nordisk’s REDEFINE 1 trial, 3,417 adults were randomly assigned to the pair, semaglutide alone, cagrilintide alone or placebo for 68 weeks, so the combination could be compared with each of its parts25.

If everyone had stayed on treatment, weight fell 22.7% with the pair, 16.1% with semaglutide alone and 11.8% with cagrilintide alone35. Even so, CagriSema is not yet approved. Novo Nordisk announced on 18 December 2025 that it had filed for FDA approval, and on 30 September 2026 it still called CagriSema investigational, with a decision expected in the fourth quarter of 20262324.

Gray-market sellers promote their own pairings. A December 2024 FDA warning letter quoted one seller’s Facebook post promising “Enhanced Weight Loss” from “Cagrilintide and Semaglutide”36. On 30 September 2026, another seller’s site code hid the names “semacargritre blend” and “cagrilinitide tre” from logged-out visitors37. Cagrilintide with retatrutide has been tested in rats, and none of the 44 cagrilintide studies on ClinicalTrials.gov, checked on 1 October 2026, gives it with retatrutide or tirzepatide3839.

Why are side effects harder to trace in a blend?

FDA has twice said it could not tell which peptide in a combined product caused a reported side effect913. Its 2026 review of BPC-157 describes a 40-year-old woman whose skin and gums darkened after she injected a “research purposes only” BPC-157 and TB-500 product, and the reaction came back when she used it again9. FDA judged the product the likely cause but, “because the product contained two peptides”, could not assess BPC-157’s role9.

FDA’s 2024 review of ipamorelin hit the same limit with a 46-year-old man who reported elbow pain after using a compounded ipamorelin and sermorelin product for 2 months. “Because the compounded product contained two peptides”, FDA could not assess ipamorelin’s role13.

Reports often name several products. As of openFDA’s 30 July 2026 update, 11 of the 12 reports naming ipamorelin in FAERS, FDA’s adverse event database, also named other products40. One, received on 17 April 2026, describes a 19-year-old man hospitalized with a reported heart attack and kidney injury who had used a CJC-1295/ipamorelin product along with tesamorelin, retatrutide and another product40. Another FAERS report, of a lymphoid cancer, listed a “GLOW” blend containing GHK-Cu as a product taken alongside the suspected drugs, hCG and Ozempic41. Such reports are unverified and cannot show which product, if any, caused an event40.

A search of FDA’s food and supplement complaint system, covering 2004 to 10 March 2025, also found two reports about “blended TB-500 and BPC-157”, but neither included a safety assessment10.

Do products match their labels?

Names on labels are not standard. FDA says products sold as BPC-157 or TB-500 come in different salts and even different active molecules under one name, so a patient may get a different substance than the one a doctor ordered910. Loose naming also hampers lab testing, FDA adds, because an analyst cannot tell which substance a reference standard, the pure sample a test is checked against, refers to910.

Labels show the confusion. FDA found a blend sold as “BPC-157 and Thymosin-beta-4 (TB 500)”, and Health Canada seized vials labeled “Thymosin-β4 (TB4 or TB-500)”942. Yet FDA defines TB-500 as a 7-amino-acid fragment of thymosin beta-4, a 43-amino-acid protein, and says the two “are not the same substance”10.

Products sold as these blends’ ingredients often fail independent tests. Finnrick, an independent testing service, failed 92 of its latest 200 BPC-157 samples (May to September 2026), 113 of its latest 200 TB-500 samples (January to September 2026), 43 of its latest 200 GHK-Cu samples (June to September 2026) and 13 of 17 KPV samples (March to September 2026)43444546. Its pass mark is at least 99.5% purity and an amount within 35% of the label, so a fail can mean the wrong substance or simply purity slightly under 99.5%4447. Its results describe the products it tested, not a random sample of the market4347.

Supplier test reports can leave out key checks: a public TB-500 certificate of analysis that FDA examined covered appearance, identity and purity, but not the amount of peptide, impurities, bacterial toxins or clumping10. A 2023 anti-doping lab study of products sold online as TB500 and TB1000 found that their contents did not consistently match their descriptions48. Health Canada warns that unauthorized peptides may contain too much, too little or none of the active ingredient49.

Compounded blends have failed checks too. Of 92 recalled sermorelin products in FDA’s records from 2012 to 2025, the two in its most serious class (Class I) were both sermorelin/GHRP-6 vials, from 2013 and 2016, and bacteria were found in the 2016 product20.

The evidence at a glance

TierBest human evidenceCompounds
ATwo or more large human trialsCagrilintide, Liraglutide, Mazdutide, Melanotan I (afamelanotide), Orforglipron, Oxytocin, PT-141 (bremelanotide), Retatrutide, Semaglutide, Survodutide, Tesamorelin, Thymosin alpha-1, Thymosin beta-4, Tirzepatide
BAt least one controlled human trialAOD-9604, BPC-157, Cerebrolysin, DSIP (emideltide), Epitalon, GHK-Cu, GHRP-2 (pralmorelin), GHRP-6, Glutathione, Gonadorelin, Hexarelin, Ipamorelin, Kisspeptin, LL-37, Melanotan II, MK-677 (ibutamoren), NAD+, Selank, Semax, Sermorelin, SS-31 (elamipretide), Thymalin, VIP (vasoactive intestinal peptide)
COnly small or uncontrolled human studiesCJC-1295
DAnimal studies onlyDihexa, KPV, MOTS-c, Pentadeca arginate (PDA), TB-500
ELab or anecdotal evidence onlyPEG-MGF

A tier grades the best human evidence for any use, not whether a compound is safe. Whether each one works for the use people take it for, and its legal status: the evidence table. How we grade: our method.

Questions people ask

Do peptide stacks work?

Nobody has shown that they do: we found no published human study of KLOW, GLOW, the Wolverine stack or CJC & Ipa789101117. In a 2026 rat study, BPC-157 with TB-500 did no better than either peptide alone33. By contrast, CagriSema, a combination drug, was compared with each of its parts in a 68-week trial of 3,417 adults25.

Is the Wolverine stack safe?

Its safety in people is unknown, because FDA found no human study of the pair and no human data for TB-500 by any route910. In one report to FDA, a woman’s skin and gums darkened after she injected a BPC-157 and TB-500 product, and FDA could not tell which peptide was responsible9.

Is KLOW peptide safe?

Nobody knows: we found no human study of KLOW, FDA found no human data for two of its peptides, TB-500 and KPV, and we found no published study that injected GHK-Cu on its own in people781012. FDA also warns that injected peptides such as BPC-157, TB-500 and KPV can trigger unwanted immune reactions91012.

Can you take tesamorelin and ipamorelin together?

No published study or registered trial has tested the pair: on 7 October 2026, PubMed held only review articles naming both, and ClinicalTrials.gov listed no trial12. Tesamorelin is approved only for excess belly fat in adults with HIV, and in August 2026 FDA called two sellers’ tesamorelin and ipamorelin blends unapproved new drugs181931.

Go deeper

Sources

  1. 1PubMed search: tesamorelin AND ipamorelin (6 results, all reviews) National Library of Medicine (PubMed), accessed 7 Oct 2026. pubmed.ncbi.nlm.nih.gov
  2. 2ClinicalTrials.gov search for ‘tesamorelin AND ipamorelin’ (0 studies) ClinicalTrials.gov, accessed 7 Oct 2026. clinicaltrials.gov
  3. 3Unauthorized health products sold online and seized at Rize Fitness may pose serious health risks (RA-81403) Health Canada, 24 Dec 2025. recalls-rappels.canada.ca
  4. 4BPC-157 10mg + TB-500 10mg (Wolverine Stack 20mg) Ascension Peptides (vendor), accessed 1 Oct 2026. ascensionpeptides.com (seller page, deliberately not linked)
  5. 5Use of experimental ‘Wolverine’ peptide backed by RFK Jr is on the rise, study finds The Independent (Reuters), 16 Sep 2026. independent.co.uk
  6. 6Prime Peptides shop page sorted by popularity Prime Peptides (vendor), accessed 30 Sep 2026. primepeptides.co (seller page, deliberately not linked)
  7. 7The copper peptide trend has gone from creams to injections — ahead of the science NPR, 7 Sep 2026. npr.org
  8. 8PubMed search: GHK-Cu or copper peptide names with injection terms (28 results; two injected people, each with a copper peptide as one ingredient of a hair-loss mixture) National Library of Medicine (PubMed), accessed 8 Oct 2026. pubmed.ncbi.nlm.nih.gov
  9. 9FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of July 23-24, 2026: BPC-157-related bulk drug substances U.S. Food and Drug Administration, 11 May 2026. fda.gov
  10. 10FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of July 23-24, 2026: TB-500-related bulk drug substances U.S. Food and Drug Administration, 15 May 2026. fda.gov
  11. 11The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration Frontiers in Endocrinology, 18 Jun 2026. frontiersin.org
  12. 12FDA Evaluation of KPV-Related Bulk Drug Substances (KPV (Free Base) and KPV Acetate), Pharmacy Compounding Advisory Committee briefing document U.S. Food and Drug Administration, 12 May 2026. fda.gov
  13. 13FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of October 29, 2024: ipamorelin-related bulk drug substances (FDA evaluation dated 19 August 2024) U.S. Food and Drug Administration, 19 Aug 2024. fda.gov
  14. 14Ascension Peptides shop page sorted by popularity Ascension Peptides (vendor), accessed 5 Oct 2026. ascensionpeptides.com (seller page, deliberately not linked)
  15. 15FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of December 4, 2024: CJC-1295-related bulk drug substances U.S. Food and Drug Administration, 15 Nov 2024. fda.gov
  16. 16Google Trends: rising related queries for ‘bpc 157’, United States, 12 months to 29 September 2026 Google Trends, accessed 30 Sep 2026. trends.google.com
  17. 17PubMed search: (“CJC-1295” OR CJC1295 OR “CJC 1295” OR “DAC:GRF” OR “modified GRF” OR “mod GRF”) (44 results) National Library of Medicine (PubMed), accessed 8 Oct 2026. pubmed.ncbi.nlm.nih.gov
  18. 18Warning letter to Royal Peptides LLC (MARCS-CMS 734884) U.S. Food and Drug Administration, 24 Aug 2026. fda.gov
  19. 19Warning letter to NuScience Peptides LLC (MARCS-CMS 733652) U.S. Food and Drug Administration, 24 Aug 2026. fda.gov
  20. 20FDA drug recall (enforcement report) records naming sermorelin, via the openFDA drug/enforcement API U.S. Food and Drug Administration (openFDA), 23 Sep 2026. api.fda.gov · data query
  21. 21Core Peptides shop page sorted by popularity Core Peptides (vendor), accessed 1 Oct 2026. corepeptides.com (seller page, deliberately not linked)
  22. 22Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels American Journal of Men’s Health, Nov 2017. pubmed.ncbi.nlm.nih.gov
  23. 23Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues for weight management Novo Nordisk (PR Newswire), 18 Dec 2025. prnewswire.com
  24. 24Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health – EASD 2026 Novo Nordisk A/S (GlobeNewswire), 30 Sep 2026. globenewswire.com
  25. 25Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1) New England Journal of Medicine, 14 Aug 2025. pubmed.ncbi.nlm.nih.gov
  26. 26Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients International Journal of Colorectal Disease, Dec 2014. pubmed.ncbi.nlm.nih.gov
  27. 27Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper Wound Repair and Regeneration, Oct 1994. pubmed.ncbi.nlm.nih.gov
  28. 28Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin Archives of Facial Plastic Surgery, Jul 2006. pubmed.ncbi.nlm.nih.gov
  29. 29Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults The Journal of Clinical Endocrinology & Metabolism, Mar 2006. pubmed.ncbi.nlm.nih.gov
  30. 30PubMed search: ipamorelin (54 results) National Library of Medicine (PubMed), accessed 8 Oct 2026. pubmed.ncbi.nlm.nih.gov
  31. 31EGRIFTA SV (tesamorelin) for injection: prescribing information (revised 2/2024) Theratechnologies via DailyMed (U.S. National Library of Medicine), Feb 2024. dailymed.nlm.nih.gov
  32. 32EGRIFTA WR (tesamorelin) for injection: prescribing information (revised 3/2025) Theratechnologies via DailyMed (U.S. National Library of Medicine), Mar 2025. dailymed.nlm.nih.gov
  33. 33Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study Joint Diseases and Related Surgery, 23 Jul 2026. pubmed.ncbi.nlm.nih.gov
  34. 34Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain Alternative Therapies in Health and Medicine, Jul 2021. pubmed.ncbi.nlm.nih.gov
  35. 35Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1 Diabetes, Obesity and Metabolism, Oct 2026. pmc.ncbi.nlm.nih.gov
  36. 36Warning letter to Summit Research Peptides (MARCS-CMS 695607) U.S. Food and Drug Administration, 10 Dec 2024. fda.gov
  37. 37Limitless Life Nootropics website (site script keyword list) Limitless Life Nootropics, accessed 30 Sep 2026. limitlesslifenootropics.com (seller page, deliberately not linked)
  38. 38Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats Nature Metabolism, 15 Sep 2026. pubmed.ncbi.nlm.nih.gov
  39. 39ClinicalTrials.gov search: studies with the intervention cagrilintide (44 records) ClinicalTrials.gov, accessed 1 Oct 2026. clinicaltrials.gov
  40. 40FDA Adverse Event Reporting System (FAERS) reports naming ipamorelin, retrieved via the openFDA drug/event API U.S. Food and Drug Administration (openFDA), 30 Jul 2026. api.fda.gov · data query
  41. 41FAERS reports listing GHK-Cu (openFDA drug adverse event endpoint) U.S. Food and Drug Administration (openFDA), 30 Jul 2026. api.fda.gov · data query
  42. 42Unauthorized injectable peptide drugs seized from Optimum Wellness Centre in Calgary, Alberta may pose serious health risks (RA-77218) Health Canada, 1 Apr 2025. recalls-rappels.canada.ca
  43. 43BPC-157 Safety Testing Results & Vendor Ratings Finnrick, 29 Sep 2026. finnrick.com
  44. 44TB-500: safety testing results and vendor ratings Finnrick, 25 Sep 2026. finnrick.com
  45. 45GHK-Cu: vendor test results Finnrick, 25 Sep 2026. finnrick.com
  46. 46KPV: safety testing results and vendor ratings Finnrick, 10 Sep 2026. finnrick.com
  47. 47Methodology Finnrick, accessed 30 Sep 2026. finnrick.com
  48. 48TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs Drug Testing and Analysis, Apr 2023. pubmed.ncbi.nlm.nih.gov
  49. 49Think twice before injecting peptides bought online: unauthorized products can seriously harm you (RA-81874) Health Canada, 9 Apr 2026. recalls-rappels.canada.ca
  50. 50Warning letter to Warrior Labz SARMS (MARCS-CMS 655280) U.S. Food and Drug Administration, 12 Jun 2023. fda.gov
  51. 51Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories list) U.S. Food and Drug Administration, 14 May 2026. fda.gov
  52. 52PEPTIDE-L WAVE! PCAC Approves Four Bulk Drug Substances for the 503A List FDA Law Blog (Hyman, Phelps & McNamara), 24 Jul 2026. thefdalawblog.com
  53. 53July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee U.S. Food and Drug Administration, 6 Aug 2026. fda.gov
  54. 54Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, December 4, 2024 U.S. Food and Drug Administration, 21 Feb 2025. fda.gov
  55. 55Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, October 29, 2024 U.S. Food and Drug Administration, 15 Jan 2025. fda.gov
  56. 56Compounding and the FDA: Questions and Answers U.S. Food and Drug Administration, 16 Sep 2025. fda.gov
  57. 57List of Approved NDAs for Biological Products That Were Deemed to be BLAs on March 23, 2020 U.S. Food and Drug Administration, accessed 1 Oct 2026. fda.gov
  58. 58Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327) Federal Register of Legislation, Australian Government, 28 Sep 2026. legislation.gov.au
  59. 59Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (F2024L00589) Federal Register of Legislation, Australian Government, 28 May 2024. legislation.gov.au
  60. 60World Anti-Doping Code International Standard: Prohibited List 2026 World Anti-Doping Agency, 24 Sep 2025. wada-ama.org
  61. 61World Anti-Doping Code International Standard: Prohibited List 2027 World Anti-Doping Agency, 21 Sep 2026. wada-ama.org
  62. 62Summary of Major Modifications and Explanatory Notes: 2027 Prohibited List World Anti-Doping Agency, 21 Sep 2026. wada-ama.org
  63. 63Triathlon Athlete Accepts Sanction for Anti-Doping Rule Violations U.S. Anti-Doping Agency, 17 Sep 2025. usada.org
  64. 64U SPORTS Volleyball Athlete Suspended for the Use of BPC-157 and TB-500 Sport Integrity Canada, 7 Apr 2025. sportintegrity.ca

Not medical advice. Nothing here recommends using any product. How we grade evidence · Report an error.